The CEO of Kite Pharma plans to initiate early conversations with insurers, even before the launch of a clinical trial of their experimental drug, to ensure smooth sailing once the product is approved and launched.
Kite Pharma Inc plans to open conversations with insurers this year to lay the groundwork for an experimental cancer treatment that could cost hundreds of thousands of dollars if it works and is approved by regulators, top executives said this week.
The possible treatment has yet to start a broad clinical trial, but the urgency comes as biotech and pharma companies consider how to navigate pushback by health insurers against GileadSciences
Inc on the price of its hepatitis C treatment.
Read the full report on Reuters: http://reut.rs/1ukdYtz
Risk for Adverse CVD Events Elevated Following Sepsis Survival
February 1st 2023Investigators found a higher overall health care burden among a large cohort of patients despite their recovery from sepsis, with potential long-term implications and higher risk of cardiovascular disease.
Read More
Promoting Health Equity and Resiliency in Trauma-Affected Communities
January 31st 2023On this episode of Managed Care Cast, we speak with Reverend Paul Abernathy, CEO of the Neighborhood Resilience Project and board member of UPMC for You, who discusses his experiences in promoting health and resiliency in trauma-affected communities, as well as challenges related to access and accessibility of care and medical mistrust.
Listen
The government is allowing Medicare Advantage (MA) plans to delay returning hundreds of millions of dollars or more in government overpayments; a proposed new extension of the Affordable Care Act (ACA) might make birth control coverage more accessible for certain private insurance plans; a study found that students lost around 33% of their school year because of the pandemic’s educational barriers and are struggling to regain that lost time.
Read More
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
First Humira Biosimilar, Amjevita, Launches in the United States
January 31st 2023The first of at least 8 adalimumab biosimilars has finally launched in the United States after being kept off the market for years due to settlement agreements with the maker of the reference product, Humira.
Read More
2 Clarke Drive
Cranbury, NJ 08512